Intelligent Bio grants restricted shares to CEO/CFO/directors; updates ATM facility

INTELLIGENT BIO SOLUTIONS INC.

CEO Harry Simeonidis and CFO Spiro Sakiris each receive 9,150 time-vesting and 21,350 performance-vesting restricted shares.
Directors awarded 20,000 time-vesting shares; non-executive employees get 10,500 time-vesting and 24,500 performance-vesting shares.
Total outstanding shares as of March 23, 2026: 2,001,173, reflecting grants and warrant exercises.
Up to $3,966,316 in shares available for sale under existing ATM agreement with Ladenburg Thalmann; new prospectus supplement filed.
Performance-vesting shares tied to clinical trial, FDA submission, and commercial milestones; vest over up to 10 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.